Solriamfetol in Binge Eating Disorder

Summary

The goal of this project is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of binge eating disorder (BED).

Timeline

Start

2021-06-15

Primary completion

2024-08-30

Completion

2024-12-30

Publications

• Guerdjikova AI, Romo-Nava F, Blom TJ, Mori N, McElroy SL. Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder. Contemp Clin Trials. 2021 Nov;110:106587. doi: 10.1016/j.cct.2021.106587. Epub 2021 Oct 2.

Drugs

Indications